



PARTICIPANT STATISTICS

THIRD QUADRIMESTER 2011

CHLAMYDIA / GC / STREP GROUP B ANTIGEN

Chlamydia

Method	Specimen 1			Specimen 2		Specimen 3		Specimen 4		Specimen 5		Pos Refer for ID
	Neg	Pos	Pos Refer for ID	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	
BD ProbeTec ET/Viper	33	2		35		1	34	1	34	33	2	
Gen-Probe APTIMA Combo 2	18	4		21	1		22	1	21	20	2	
Gen-Probe Pace 2	6	2		8		1	7	1	7	7	1	
Inverness Clearview	15			15			15		15	14	1	
Quidel QuickVue	12			12			12		12	12		
Roche Amplicor	7			7			7		7	7		
Total Population	91	8	0	98	1	2	97	3	96	93	6	0
Flagging	*****			*****		*****		*****		*****		

Neisseria gonorrhoeae

Method	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5		No. of Labs
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	
BD ProbeTec ET/Viper	2	30	32		31	1	31	1	1	31	32
Gen-Probe APTIMA Combo 2	1	21	22		22		21	1	1	21	22
Gen-Probe Pace 2	1	6	7		6	1	6	1	1	6	7
Roche Amplicor		7	7		7		7			7	7
Total Population	4	67	71	0	69	2	68	3	3	68	71
Flagging	*****			*****		*****		*****	*****		

Strep Group B

Method	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5		No. of Labs
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	
BD Directigen-latex	2	1		3	2	1	2	1	2	1	3
Gen-Probe AccuProbe	2			2	2		2		2		2
Remel Wellcogen	1			1	1		1		1		1
Remel PathoDX	2			2	2		2		2		2
Total Population	7	1	0	8	7	1	7	1	7	1	8
Flagging	*****		*****			*****		*****		*****	

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.